Lv51
950 积分 2023-08-02 加入
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
13天前
已完结
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
13天前
已完结
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?
14天前
已完结
Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage
1个月前
已完结
Advances in structural-guided modifications of siRNA
1个月前
已完结
Targeting hepatic macrophages to treat liver diseases
2个月前
已完结
Macrophage‐specific FGF12 promotes liver fibrosis progression in mice
2个月前
已完结
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?
2个月前
已完结
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial
3个月前
已完结
Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
3个月前
已完结
皖公网安备34019202002308
